High Dose IL 2 and Entinostat in RCC

NCT03501381 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Entinostat
DRUG: Interleukin-2

Sponsor

Roberto Pili

Collaborators

[object Object]
[object Object]
[object Object]